Biomarkers & Genomics

Biomarkers & Genomics

Recently marketed oncology drugs are targeting specific proteins overexpressed in cancer. They only benefit patients with tumor cells carrying specific genetic features which are to be tested prior to the administration of the drug. Therefore, BARC offers predictive tests for targeted therapies to be performed directly on the tumor using the latest techniques both in histopathology and molecular biology.

Pharmacogenomics

Host-related characteristics often play a critical role in treatment indication, dosage, tolerance, efficacy and occurrence of side effects. BARC’s experts have implemented several techniques and set up many in-house sequencing tests for assaying genetic characteristics involved in individual response to drug. Pharmacogenomics are a cornerstone of personalized medicine and more and more clinical trials require those tests to precisely assess the added value of a new drug. BARC’s specialists are highly aware of the requirements for a pharmacogenomic assay to become a companion diagnostic test as all our laboratories have a clinical pathology activity servicing the community. Their expertise in this field is invaluable for optimizing the trials and transferring those tests into clinical routine.